BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 21095073)

  • 1. Progression of non-small-cell lung cancer during the interval before stereotactic body radiotherapy.
    Murai T; Shibamoto Y; Baba F; Hashizume C; Mori Y; Ayakawa S; Kawai T; Takemoto S; Sugie C; Ogino H
    Int J Radiat Oncol Biol Phys; 2012 Jan; 82(1):463-7. PubMed ID: 21095073
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tumor volume change with stereotactic body radiotherapy (SBRT) for early-stage lung cancer: evaluating the potential for adaptive SBRT.
    Bhatt AD; El-Ghamry MN; Dunlap NE; Bhatt G; Harkenrider MM; Schuler JC; Zacarias A; Civelek AC; Pan J; Rai SN; Woo SY
    Am J Clin Oncol; 2015 Feb; 38(1):41-6. PubMed ID: 24513663
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical outcomes of stage I and IIA non-small cell lung cancer patients treated with stereotactic body radiotherapy using a real-time tumor-tracking radiotherapy system.
    Katoh N; Soda I; Tamamura H; Takahashi S; Uchinami Y; Ishiyama H; Ota K; Inoue T; Onimaru R; Shibuya K; Hayakawa K; Shirato H
    Radiat Oncol; 2017 Jan; 12(1):3. PubMed ID: 28057036
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Changes in volume of stage I non-small-cell lung cancer during stereotactic body radiotherapy.
    Tatekawa K; Iwata H; Kawaguchi T; Ishikura S; Baba F; Otsuka S; Miyakawa A; Iwana M; Shibamoto Y
    Radiat Oncol; 2014 Jan; 9():8. PubMed ID: 24393430
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 7-year follow-up after stereotactic ablative radiotherapy for patients with stage I non-small cell lung cancer: Results of a phase 2 clinical trial.
    Sun B; Brooks ED; Komaki RU; Liao Z; Jeter MD; McAleer MF; Allen PK; Balter PA; Welsh JD; O'Reilly MS; Gomez D; Hahn SM; Roth JA; Mehran RJ; Heymach JV; Chang JY
    Cancer; 2017 Aug; 123(16):3031-3039. PubMed ID: 28346656
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cone-beam CT radiomics features might improve the prediction of lung toxicity after SBRT in stage I NSCLC patients.
    Qin Q; Shi A; Zhang R; Wen Q; Niu T; Chen J; Qiu Q; Wan Y; Sun X; Xing L
    Thorac Cancer; 2020 Apr; 11(4):964-972. PubMed ID: 32061061
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Stereotactic Body Radiation Therapy for Non-Small Cell Lung Cancer Tumors Greater Than 5 cm: Safety and Efficacy.
    Woody NM; Stephans KL; Marwaha G; Djemil T; Videtic GM
    Int J Radiat Oncol Biol Phys; 2015 Jun; 92(2):325-31. PubMed ID: 25841625
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of pretreatment tumor growth rate on outcome of early-stage lung cancer treated with stereotactic body radiation therapy.
    Atallah S; Cho BC; Allibhai Z; Taremi M; Giuliani M; Le LW; Brade A; Sun A; Bezjak A; Hope AJ
    Int J Radiat Oncol Biol Phys; 2014 Jul; 89(3):532-8. PubMed ID: 24929163
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Consequences of Referral Time and Volume Doubling Time in Inoperable Patients With Early Stage Lung Cancer.
    Frelinghuysen M; Fest J; Van der Voort Van Zyp NC; Van der Holt B; Hoogeman M; Nuyttens J
    Clin Lung Cancer; 2017 Nov; 18(6):e403-e409. PubMed ID: 28571689
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A retrospective study of volume doubling time in surgically resected non-small cell lung cancer.
    Mackintosh JA; Marshall HM; Yang IA; Bowman RV; Fong KM
    Respirology; 2014 Jul; 19(5):755-62. PubMed ID: 24797504
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Histologic Basis for the Efficacy of SBRT to the lung.
    Woody NM; Stephans KL; Andrews M; Zhuang T; Gopal P; Xia P; Farver CF; Raymond DP; Peacock CD; Cicenia J; Reddy CA; Videtic GM; Abazeed ME
    J Thorac Oncol; 2017 Mar; 12(3):510-519. PubMed ID: 28017592
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A SUV
    Ye L; Xu F; Shi S; Zeng Z; Jin X; Huang Y; Lu C; Gu J; Ge D; He J
    Clin Transl Oncol; 2018 Aug; 20(8):1026-1034. PubMed ID: 29327241
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Survival and treatment of non-small cell lung cancer stage I-II treated surgically or with stereotactic body radiotherapy: patient and tumor-specific factors affect the prognosis.
    Mokhles S; Nuyttens JJ; Maat AP; Birim Ö; Aerts JG; Bogers AJ; Takkenberg JJ
    Ann Surg Oncol; 2015 Jan; 22(1):316-23. PubMed ID: 24962941
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of tumor attachment to the pleura measured by a pretreatment CT image on outcome of stage I NSCLC treated with stereotactic body radiotherapy.
    Yamamoto T; Kadoya N; Shirata Y; Koto M; Sato K; Matsushita H; Sugawara T; Umezawa R; Kubozono M; Ishikawa Y; Kozumi M; Takahashi N; Ito K; Katagiri Y; Takeda K; Jingu K
    Radiat Oncol; 2015 Feb; 10():35. PubMed ID: 25886315
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The impact of tumor size on outcomes after stereotactic body radiation therapy for medically inoperable early-stage non-small cell lung cancer.
    Allibhai Z; Taremi M; Bezjak A; Brade A; Hope AJ; Sun A; Cho BC
    Int J Radiat Oncol Biol Phys; 2013 Dec; 87(5):1064-70. PubMed ID: 24210082
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Stereotactic body radiotherapy for primary lung cancer at a dose of 50 Gy total in five fractions to the periphery of the planning target volume calculated using a superposition algorithm.
    Takeda A; Sanuki N; Kunieda E; Ohashi T; Oku Y; Takeda T; Shigematsu N; Kubo A
    Int J Radiat Oncol Biol Phys; 2009 Feb; 73(2):442-8. PubMed ID: 18990507
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lack of a dose-effect relationship for pulmonary function changes after stereotactic body radiation therapy for early-stage non-small cell lung cancer.
    Guckenberger M; Klement RJ; Kestin LL; Hope AJ; Belderbos J; Werner-Wasik M; Yan D; Sonke JJ; Bissonnette JP; Xiao Y; Grills IS
    Int J Radiat Oncol Biol Phys; 2013 Mar; 85(4):1074-81. PubMed ID: 23154077
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Stereotactic body radiotherapy for centrally located early-stage non-small cell lung cancer or lung metastases from the RSSearch(®) patient registry.
    Davis JN; Medbery C; Sharma S; Pablo J; Kimsey F; Perry D; Muacevic A; Mahadevan A
    Radiat Oncol; 2015 May; 10():113. PubMed ID: 25975848
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dose-response relationship for image-guided stereotactic body radiotherapy of pulmonary tumors: relevance of 4D dose calculation.
    Guckenberger M; Wulf J; Mueller G; Krieger T; Baier K; Gabor M; Richter A; Wilbert J; Flentje M
    Int J Radiat Oncol Biol Phys; 2009 May; 74(1):47-54. PubMed ID: 18977095
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparative efficacy and toxicity of induction chemotherapy with concurrent stereotactic body radiotherapy and stereotactic body radiotherapy with subsequent chemotherapy in patients with clinical stage T1-3N0M0 non-small cell lung carcinoma.
    Sun Y; Duan Q; Chen X; Chen W; Jin X; Wu R
    Clin Transl Oncol; 2017 Dec; 19(12):1498-1506. PubMed ID: 28589432
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.